Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesN4 Pharma PLC

N4 Pharma PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-06-12T07:36:35.125716Z
Market Cap
3.95M

Momentum Score

…

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.35
Low
1.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.68
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
-
ROE
-74.18%
Net Debt
-0.63M
ROCE
-187.44%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.22M -1.43M -1.19M -1.84M -1.57M
Minority interest 0.06M 0.01M - - -
Net income -1.06M -1.27M -1.03M -1.54M -1.30M
Selling general administrative 0.55M 0.72M 0.62M 0.66M 0.66M
Selling and marketing expenses - 0.09M - - -
Gross profit 0.01M 0.00M - - -
Ebit - -1.42M -1.19M -1.84M -1.56M
Ebitda -1.22M -1.33M -1.19M -1.84M -1.56M
Depreciation and amortization - 0.09M - - -
Operating income -1.22M -1.43M -1.19M -1.84M -1.56M
Other operating expenses 1.23M 1.43M 1.19M 1.84M 1.56M
Interest expense - - 0.00M 0.00M 0.00M
Tax provision -0.10M -0.15M -0.16M -0.30M -0.26M
Interest income - 0.00M 0.00M 0.00M 0.00M
Net interest income - 0.00M 0.00M 0.00M -0.00M
Income tax expense -0.10M -0.15M -0.16M -0.30M -0.26M
Total revenue 0.01M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.17M 1.43M 1.19M 1.84M 1.56M
Total other income expense net - -0.00M 0.00M 0.00M -0.00M
Net income from continuing ops -1.12M -1.28M -1.03M -1.54M -1.30M
Net income applicable to common shares - - -1.03M -1.54M -1.30M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.78M 1.28M 2.17M 2.34M 3.83M
Other current assets 0.02M 0.01M 0.25M 0.56M 0.27M
Total liab 0.12M 0.08M 0.08M 0.21M 0.17M
Total stockholder equity 0.65M 1.13M 2.09M 2.13M 3.66M
Other current liab 0.10M 0.07M 0.04M 0.03M 0.05M
Common stock 1.58M 9.35M 0.94M 0.72M 0.72M
Capital stock 1.58M 1.08M 0.94M 0.72M 0.72M
Retained earnings -10.40M -9.34M -8.06M -7.03M -5.49M
Good will 0.00M 0.06M - - -
Other assets - 0.00M - - -
Cash 0.63M 1.03M 1.92M 1.78M 3.56M
Total current liabilities 0.12M 0.08M 0.08M 0.21M 0.17M
Net debt -0.63M -1.03M -1.92M -1.78M -3.56M
Other stockholder equity 9.47M 1.02M 9.21M 8.44M 8.42M
Total current assets 0.78M 1.21M 2.17M 2.34M 3.83M
Net tangible assets - - 2.09M 2.13M 3.66M
Net receivables 0.13M 0.18M 0.21M 0.56M 0.25M
Inventory - -0.18M - - -
Accounts payable 0.02M 0.02M 0.04M 0.18M 0.12M
Accumulated other comprehensive income 0.11M 0.11M - - -
Common stock total equity - - - - 0.72M
Non currrent assets other - -0.00M - - -
Non current assets total 0.00M 0.06M 0.00M 0.00M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.00M 0.00M - - 0.00M
Change to liabilities - - -0.13M 0.04M 0.09M
Total cashflows from investing activities - 0.00M - - -
Total cash from financing activities 0.57M 0.32M 0.96M 0.00M 3.97M
Net income -1.12M -1.27M -1.03M -1.54M -1.57M
Change in cash -0.40M -0.89M 0.14M -1.77M 2.59M
Begin period cash flow 1.03M 1.92M 1.78M 3.56M 0.97M
End period cash flow 0.63M 1.03M 1.92M 1.78M 3.56M
Total cash from operating activities -0.97M -1.21M -0.83M -1.77M -1.38M
Issuance of capital stock 0.63M 0.35M 1.05M 0.00M 3.97M
Change to account receivables -0.01M 0.04M -0.04M 0.01M -0.03M
Sale purchase of stock - - - - 3.97M
Other cashflows from financing activities -0.06M -0.03M -0.09M 0.00M -0.00M
Change to netincome - - 0.37M -0.28M -0.26M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.03M 0.05M -0.17M 0.05M 0.06M
Stock based compensation 0.01M 0.00M 0.02M 0.02M 0.00M
Other non cash items 0.11M 0.01M 0.35M -0.30M 0.12M
Free cash flow -0.97M -1.21M -0.83M -1.77M -1.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

N4 Pharma PLC

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

8 Bishopsgate, London, United Kingdom, EC2N 4BQ

44 1332 690061

https://www.n4pharma.com

4

Name Title Year Born
Mr. Nigel James Theobald Founder, CEO & Exec. Director 1964
Dr. David Templeton Exec. Director & Technical Director NA
Mr. Luke Sebastian Cairns Exec. Director 1978
Rob Harris Head of CMC Devel. NA
Dr. Andrew Leishman Consultant NA
Mr. Luke Sebastian Cairns Executive Director 1978
Dr. David Horn Solomon M.D. CEO & Director 1960
Rob Harris Head of CMC Development NA
Dr. Fiona McLaughlin FSB, Ph.D. Head of Research & Development 1970
Mr. Mark Edbrooke Ph.D. Head of Strategy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…